staphylococcu
aureu
mrsa
caus
lifethreaten
necrot
pneumonia
children
sporad
incid
preclud
evalu
antimicrobi
efficaci
assess
clinic
characterist
outcom
critic
ill
children
influenzamrsa
pneumonia
evalu
antibiot
use
method
enrol
children
year
influenza
infect
respiratori
failur
across
pediatr
intens
care
unit
compar
baselin
characterist
clinic
cours
therapi
children
mrsa
coinfect
nonmrsa
bacteri
coinfect
bacteri
coinfect
result
enrol
children
influenza
influenza
b
children
influenzamrsa
pneumonia
n
previous
healthi
older
nonmrsa
n
n
bacteri
coinfect
influenzamrsa
associ
increas
leukopenia
acut
lung
injuri
vasopressor
use
extracorpor
life
support
mortal
either
group
p
influenzarel
mortal
mrsa
compar
without
rel
risk
rr
confid
interv
ci
children
mrsa
receiv
vancomycin
within
first
hour
hospit
mortal
n
treatment
also
includ
second
antimrsa
antibiot
compar
n
vancomycin
monotherapi
rr
ci
p
vancomycin
dose
influenc
initi
trough
level
conclus
influenzamrsa
coinfect
associ
high
fatal
critic
ill
children
data
support
earli
addit
second
antimrsa
antibiot
vancomycin
suspect
sever
case
previous
healthi
children
rigor
evalu
optim
antimicrobi
therapeut
strategi
improv
clinic
outcom
devast
combin
imped
sporad
occurr
fulmin
cours
although
children
confirm
suspect
identifi
across
us
pediatr
intens
care
unit
picu
case
mrsa
coinfect
report
intraven
vancomycin
clindamycin
recommend
mainstay
therapi
treatment
hospit
children
communityacquir
ca
pneumonia
cap
mrsa
suspect
addit
second
antimrsa
agent
controversi
partli
combin
commonli
use
antibiot
mrsa
linezolid
vancomycin
shown
antagonist
effect
anim
model
invas
mrsa
infect
experiment
vitro
assay
studi
anim
observ
data
j
r
r
c
l
e
human
show
aureu
toxin
like
drive
system
inflamm
immun
suppress
lung
necrosi
therapi
target
specif
aureu
toxin
current
evalu
random
trial
yet
clinic
avail
staphylococcu
aureu
antivirul
effect
report
vitro
clindamycin
reduc
staphylococc
protein
express
pantonvalentin
leukocidin
express
alpha
hemolysin
express
camrsa
clinic
aureu
strain
betalactam
antibiot
associ
increas
aureu
toxin
express
vitro
vancomycin
neglig
effect
absenc
clinic
trial
data
observ
studi
realworld
practic
may
give
insight
guid
therapi
therefor
multicent
observ
studi
critic
ill
children
confirm
influenza
infect
pediatr
intens
care
influenza
picflu
studi
character
clinic
present
immun
respons
clinic
outcom
influenzamrsa
respiratori
coinfect
compar
critic
ill
children
influenza
coinfect
nonmrsa
bacteria
diagnosi
bacteri
coinfect
also
aim
examin
use
antimicrobi
therapi
children
influenzamrsa
coinfect
hypothes
variabl
would
high
would
associ
mortal
patient
age
year
confirm
ca
influenza
infect
respiratori
failur
receiv
invas
mechan
ventil
admit
picu
voluntarili
particip
picflu
studi
prospect
enrol
decemb
may
site
pediatr
acut
lung
injuri
sepsi
investig
network
palisi
detail
method
picflu
studi
report
exclud
patient
preexist
lung
disord
immun
compromis
mitochondri
genet
neurolog
disord
andor
preexist
cardiac
diseas
increas
risk
infect
respiratori
failur
patient
nonsubtyp
influenza
also
exclud
institut
review
board
site
gave
studi
approv
inform
consent
obtain
parent
guardian
throughout
studi
period
site
encourag
follow
recommend
publish
cdc
screen
symptomat
patient
admit
picu
influenza
test
intub
patient
secondari
bacteri
infect
gram
stain
cultur
endotrach
secret
patient
manag
clinician
discret
first
studi
sampl
taken
soon
possibl
picu
admiss
includ
respiratori
sampl
nasopharynx
endotrach
tube
ett
viral
test
result
includ
clinic
site
could
perform
prior
picu
admiss
well
addit
studi
test
done
marshfield
clinic
research
foundat
marshfield
wi
influenza
viral
test
method
previous
report
virus
test
includ
respiratori
syncyti
viru
human
metapneumoviru
human
rhinoviru
parainfluenza
viru
influenza
b
includ
subtyp
coronaviru
adenoviru
bacteri
coinfect
defin
diagnosi
clinic
site
microbiolog
identif
pathogen
within
hour
prior
picu
admiss
rule
hospitalacquir
infect
cultur
come
steril
site
endotrach
bronchoscop
specimen
bloodstream
pleural
fluid
posit
test
mrsa
colon
screen
alon
insuffici
determin
bacteri
coinfect
race
ethnic
captur
parent
interview
pediatr
risk
mortal
iii
acut
physiolog
prism
iii
score
measur
sever
ill
within
hour
picu
admiss
invas
mechan
ventil
via
ett
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
acut
onset
respiratori
distress
hypoxia
pao
fio
ratio
ali
ard
bilater
infiltr
chest
radiograph
evid
left
heart
failur
shock
requir
vasopressor
support
use
dopamin
infus
epinephrin
norepinephrin
phenylephrin
infus
maintain
blood
pressur
mortal
death
index
hospit
site
investig
collect
data
baselin
demograph
inform
ill
durat
present
symptom
initi
picu
admiss
find
select
clinic
event
outcom
hospit
picu
discharg
data
enter
redcap
electron
case
report
form
host
secur
server
boston
children
hospit
record
baselin
valu
laboratori
result
vital
sign
vasoactiveinotrop
dose
chest
radiograph
result
oxygen
first
record
valu
picu
valu
unavail
valu
closest
admiss
transport
emerg
depart
referr
hospit
use
data
collect
close
possibl
data
consid
miss
valu
avail
final
outcom
survivaldeath
track
initi
picu
discharg
date
patient
hospit
discharg
patient
transfer
ward
data
antibiot
given
first
hour
picu
admiss
prior
picu
admiss
collect
prospect
children
influenzamrsa
coinfect
site
collect
inform
time
antibiot
prior
picu
admiss
well
vancomycin
trough
level
vancomycin
dose
antibiot
suscept
test
result
retrospect
sampl
blood
endotrach
aspir
intub
taken
enrol
within
hour
picu
admiss
day
later
still
picu
ett
aspir
kept
ice
centrifug
ett
supernat
aliquot
store
concentr
cytokin
measur
duplic
univers
minnesota
cytokin
refer
laboratori
use
standard
enzymelink
immunosorb
assay
well
beadbas
luminex
multiplex
assay
luminex
platform
austin
tx
describ
detail
recent
public
statist
analysi
perform
use
sa
softwar
version
cari
nc
categor
variabl
compar
use
fisher
exact
test
mannwhitney
u
test
continu
variabl
analyz
use
spearman
correl
kruskalw
test
dunn
test
posthoc
analys
logist
regress
adjust
age
prism
iii
score
use
confirm
associ
mortal
earli
vancomycin
monotherapi
vs
addit
earli
antimrsa
antibiot
group
enrol
children
met
inclus
exclus
criteria
across
site
novemb
may
shown
tabl
tabl
detail
clinic
diagnosi
bacteri
coinfect
children
mrsa
coinfect
posit
mrsa
cultur
endotrach
aspir
pleural
fluid
andor
lung
tissu
also
mrsa
bacteremia
demograph
characterist
underli
health
condit
clinic
cours
outcom
group
children
shown
tabl
children
mrsa
averag
time
older
children
nonmrsa
group
p
like
previous
healthi
p
children
influenza
alon
children
influenzamssa
coinfect
overal
baselin
characterist
clinic
outcom
similar
influenza
coinfect
non
aureu
bacteria
detail
shown
supplementari
tabl
p
except
averag
older
depict
figur
children
mrsa
coinfect
acut
lung
injuri
vasopressor
use
shock
compar
approxim
half
nonmrsa
comparison
group
p
mrsa
patient
receiv
extracorpor
membran
oxygen
ecmo
support
compar
less
group
p
influenzarel
mortal
mrsa
coinfect
compar
without
mrsa
rel
risk
rr
confid
interv
ci
one
child
sever
lung
necrosi
support
ecmo
month
die
soon
receiv
lung
transplant
autopsi
result
avail
mrsa
patient
die
ecmo
support
show
extens
area
hemorrhag
infarct
abscess
format
necrosi
emboli
lung
pleural
adhes
effus
death
mrsacoinfect
patient
associ
older
age
p
higher
prism
iii
score
p
type
influenza
viru
infect
see
supplementari
tabl
site
mrsa
cultur
bacteremia
supplementari
tabl
although
statist
signific
p
children
die
reportedli
vaccin
influenza
season
vaccin
unavail
compar
survivor
vaccin
unavail
time
first
symptom
onset
picu
admiss
avail
parent
interview
start
fall
children
die
surviv
median
day
picu
present
interquartil
rang
iqr
vs
iqr
respect
p
shown
figur
influenzamrsacoinfect
children
markedli
suppress
white
blood
cell
wbc
count
first
hour
picu
admiss
compar
nonmrsa
influenza
group
p
mssacoinfect
children
admissionday
wbc
valu
similar
coinfect
bacteria
supplementari
tabl
children
differenti
avail
profound
neutropenia
com
choic
earli
within
first
hour
picu
admiss
antimrsa
antibiot
administr
children
influenzamrsa
coinfect
vari
one
child
die
receiv
earli
clindamycin
monotherapi
earli
vancomycin
given
patient
n
figur
show
whether
addit
earli
antimrsa
antibiot
receiv
patient
stratifi
children
hospit
surviv
although
n
receiv
vancomycin
monotherapi
n
receiv
addit
therapi
commonli
clindamycin
children
receiv
third
earli
antimrsa
antibiot
receiv
ceftarolin
receiv
linezolid
receiv
ceftarolin
plu
vancomycin
age
gender
prism
iii
score
type
influenza
infect
influenza
vaccin
significantli
differ
earli
vancomycin
monotherapi
addit
earli
antimrsa
antibiot
group
see
supplementari
tabl
mortal
n
receiv
earli
vancomycin
monotherapi
compar
n
receiv
vancomycin
second
antimrsa
agent
within
first
hour
rr
ci
p
estim
number
need
treat
antimrsa
agent
prevent
death
would
ci
find
remain
signific
p
adjust
ill
sever
first
hour
prism
iii
score
age
major
children
surviv
die
receiv
extracorpor
life
support
children
data
avail
time
present
receiv
vancomycin
monotherapi
addit
antimrsa
therapi
report
median
time
symptom
onset
present
day
iqr
vs
day
iqr
respect
p
even
imput
percentil
respect
time
present
miss
data
day
death
day
survivor
time
present
would
reach
statist
signific
group
children
vancomycinonli
group
miss
data
survivor
test
mrsa
isol
suscept
clindamycin
n
mrsa
isol
test
minimum
inhibitori
concentr
mic
test
mrsa
isol
vancomycin
children
report
abl
obtain
first
vancomycin
trough
level
children
mrsa
receiv
vancomycin
first
hour
exclud
patient
acut
renal
failur
admiss
whose
vancomycin
dose
requir
adjust
shown
figur
initi
vancomycin
trough
level
vancomycin
dose
associ
vancomycin
trough
level
figur
children
influenzarel
acut
respiratori
failur
multicent
picu
cohort
mrsa
coinfect
sever
ill
children
coinfect
bacteria
bacteri
coinfect
time
like
die
antimrsa
antibiot
given
within
hour
picu
admiss
associ
hospit
outcom
children
receiv
earli
vancomycin
sole
antimrsa
agent
time
higher
risk
mortal
children
receiv
earli
vancomycin
plu
earli
addit
anoth
antimrsa
agent
choic
antimicrobi
therapi
mostli
empir
bacteri
diagnosi
usual
take
longer
hour
factor
distinguish
influenzamrsacoinfect
children
major
adolesc
previous
healthi
usual
develop
leukopenia
first
picu
day
frequent
neutropenia
despit
higher
gcsf
serum
level
often
cannul
ecmo
support
earli
recognit
patient
profil
could
guid
choic
empir
therapi
difficulti
reach
therapeut
level
vancomycin
pediatr
patient
good
renal
clearanc
common
consist
improv
addit
vancomycin
load
dose
areaunderthecurv
auc
mic
ratio
posit
potenti
better
predictor
vancomycin
efficaci
vancomycin
trough
level
howev
clinic
outcom
report
improv
even
adequ
auc
mic
earli
invas
mrsa
infect
investig
systemat
review
avail
studi
conclud
vancomycin
poorli
penetr
lung
tissu
compar
simultan
plasma
level
concentr
lung
epitheli
line
fluid
rang
concentr
whole
homogen
lung
tissu
rang
mrsa
suscept
clindamycin
second
commonli
prescrib
antimrsa
agent
near
univers
cohort
unfortun
suscept
aureu
clindamycin
may
declin
us
children
via
mechan
protein
synthesi
inhibit
present
vancomycin
clindamycin
antitoxin
effect
vitro
although
data
vitro
model
also
suggest
antagon
exist
vancomycin
combin
clindamycin
linezolid
poor
agreement
anim
human
model
antibiot
antagon
synergi
treat
mrsa
ultim
choic
second
antimrsa
agent
influenc
local
mrsa
antibiogram
ceftarolin
clinic
approv
mrsacap
skin
soft
tissu
infect
use
surviv
patient
adjunct
antibiot
vancomycin
rigor
pharmacokinet
outcom
data
ceftarolin
treatment
intub
children
mrsa
pneumonia
lack
strength
studi
includ
prospect
enrol
rigor
data
collect
sensit
influenza
test
clinic
care
control
reveal
high
practic
variabl
across
center
empir
choic
dose
time
vancomycin
use
addit
antimrsa
antibiot
studi
numer
limit
design
observ
cohort
mrsa
patient
rel
small
includ
mrsacoinfect
patient
mrsarel
death
despit
involv
larg
picu
year
children
sever
comorbid
health
condit
predispos
influenza
infect
exclud
limit
generaliz
decreas
potenti
confound
durat
symptom
prior
initi
present
avail
earli
studi
analysi
avail
data
time
present
sensit
analysi
show
although
longer
time
symptom
onset
picu
admiss
associ
increas
fatal
unlik
explain
associ
vancomycin
monotherapi
death
collect
data
antimicrobialrel
advers
event
would
difficult
given
high
rate
multiorgan
failur
picu
admiss
mrsacoinfect
children
import
note
mrsa
coinfect
occur
virus
focu
influenza
viru
infect
could
determin
clinic
cours
outcom
mrsa
coinfect
noninfluenza
viral
infect
similar
although
limit
realworld
evid
antibiot
efficaci
pediatr
influenzamrsa
coinfect
sporad
fulmin
diseas
high
fatal
indic
vancomycin
alon
insuffici
therapi
children
picu
acut
respiratori
failur
result
diagnost
test
mrsa
influenza
delay
hour
empir
therapi
may
need
optim
clinic
outcom
older
age
prior
good
health
well
leukopenia
shock
requir
vasopressor
support
present
associ
mrsa
coinfect
thu
patient
present
acut
respiratori
distress
similar
featur
influenza
season
prompt
consider
addit
antimrsa
antibiot
diagnost
studi
pend
although
addit
clindamycin
vancomycin
appear
prudent
case
high
clinic
suspicion
influenzamrsa
coinfect
clindamycin
resist
must
monitor
nation
ongo
registri
fatal
pediatr
coinfect
antimicrobi
suscept
antibiot
manag
collect
clinic
sampl
could
help
guid
care
addit
adjunct
therapi
antibodi
target
aureu
toxin
may
decreas
mortal
children
mrsa
coinfect
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
note
marita
thompson
univers
texa
southwestern
medic
center
dalla
laura
l
lofti
nanci
jaimon
texa
children
hospit
houston
dougla
f
wilson
univers
virginia
children
hospit
charlottesvil
rainer
g
gedeit
kathi
murkowski
katherin
siegel
children
hospit
wisconsin
milwauke
duga
centr
hospitali
de
laval
quebec
canada
disclaim
work
repres
find
author
necessarili
view
nation
institut
health
nih
us
center
diseas
control
prevent
cdc
financi
support
work
support
nih
nation
institut
allergi
infecti
diseas
agr
cdc
agr
km
acknowledg
support
boston
children
hospit
translat
research
program
charl
hood
foundat
potenti
conflict
interest
ar
report
consult
fee
bristol
myer
squibb
la
jolla
pharmaceut
genentech
inc
mh
report
consult
fee
form
bristol
myer
squibb
grant
nih
sw
report
consult
fee
bristol
myer
squibb
grant
societi
critic
care
medicin
travel
accommod
thermofish
scientif
royalti
uptod
nt
report
consult
fee
therabron
care
fusion
gene
fluidic
author
report
potenti
conflict
interest
author
submit
icmj
form
disclosur
potenti
conflict
interest
conflict
editor
consid
relev
content
manuscript
disclos
